Cargando…

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort

BACKGROUND: MammaPrint is a prognostic assay based on gene expression in tumors from patients with early breast cancer. MammaPrint has been extensively validated and Food and Drug Administration cleared in fresh and formalin-fixed and paraffin-embedded (FFPE) tissue. We aimed to assess its prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubsky, P., Van't Veer, L., Gnant, M., Rudas, M., Bago-Horvath, Z., Greil, R., Lujinovic, E., Buresch, J., Rinnerthaler, G., Hulla, W., Moinfar, F., Egle, D., Herz, W., Dreezen, C., Frantal, S., Filipits, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807937/ https://www.ncbi.nlm.nih.gov/pubmed/33399073 http://dx.doi.org/10.1016/j.esmoop.2020.100006

Ejemplares similares

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial
por: Fitzal, F, et al.
Publicado: (2021)

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016)

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
por: Filipits, M., et al.
Publicado: (2021)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016)

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
por: Haan, Josien C., et al.
Publicado: (2021)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
por: Fatima, Areej, et al.
Publicado: (2017)

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Myburgh, Ettienne J., et al.
Publicado: (2021)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18
por: Minichsdorfer, C., et al.
Publicado: (2022)

A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Lee, Young Joo, et al.
Publicado: (2021)

RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Mansani, Fabio Postiglione, et al.
Publicado: (2022)

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
por: Espinel, C. Francisco, et al.
Publicado: (2012)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019)

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013)

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Hwang, Young Sol, et al.
Publicado: (2022)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction
por: Yao, Kevin, et al.
Publicado: (2022)

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer
por: Tian, Sun, et al.
Publicado: (2010)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial
por: Bjelic-Radisic, V., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
por: Blank, Patricia R., et al.
Publicado: (2014)

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
por: Slembrouck, Laurence, et al.
Publicado: (2019)

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
por: Pan, Bo, et al.
Publicado: (2023)

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing
por: Bai, Qianming, et al.
Publicado: (2023)

Prognostic impact of breast cancer subtypes in elderly patients
por: Bergen, E. S., et al.
Publicado: (2016)

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Blumencranz, Peter, et al.
Publicado: (2023)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a4i6jgju68iop1qi7h6s6qpo0r